Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) [Trend Analysis] try to make new thrust in street and making different trends, stocks trading ended with 4.57% to $1.83. Eisai Inc. and Arena Pharmaceuticals, Inc. (ARNA) released the availability of Belviq XR, or lorcaserin Hcl, CIV extended-release 20 mg tablets, a new once-daily dosing option that may help some patients achieve and maintain weight loss. According to the companies, Belviq XR is proven to be slowly absorbed in the body and last all through the day.
The 20 mg once-daily extended-release formulation is agreed for use with a reduced-calorie diet and surged physical activity for chronic weight management in adults who have a body mass index or BMI of 30 kg/m2 or greater (obese), or BMI of 27 kg/m2 or greater (overweight) with at least one weight-related medical condition, such as high blood pressure, high cholesterol or type 2 diabetes.
The share price of ARNA attracts active investors, as stock price of week volatility recorded 4.94%. The stock is going forward to its 52-week low with 40.77% and lagging behind from its 52-week high price with -31.72%.
Merck & Co., Inc. (NYSE:MRK) [Trend Analysis] surged reacts as active mover, shares an raise 0.18% to traded at $62.52 and the percentage gap among open changing to regular change was -0.30%. Merck (MRK) released that new data from the firm’s chronic hepatitis C virus or HCV clinical development programs will be presented at The Liver Meeting 2016. Fifteen scientific abstracts, comprising seven oral and eight poster presentations, will highlight findings from Merck’s HCV clinical development programs.
The data include evaluations of ZEPATIER (elbasvir and grazoprevir) 50mg/100mg tablets and the firm’s examinational MK-3682B (MK-36821/grazoprevir2/rusazvir) in a broad range of patients with chronic HCV infection. The Liver Meeting 2016 will take place in Boston, MA, from November 11-15, 2016. ZEPATIER is a fixed-dose combination product containing elbasvir, a HCV NS5A inhibitor, and grazoprevir, an HCV NS3/4A protease inhibitor.
In the United States, ZEPATIER is indicated with or without ribavirin (RBV) for treatment of chronic HCV GT1 or 4 infection in adults. ZEPATIER is not indicated to treat chronic HCV GT3 or GT6 infection. ZEPATIER was agreed in the U.s.on January 28, 2016 and is also agreed in the Eu, Canada, Japan, Australia, Saudi Arabia, Israel and Switzerland, with additional regulatory authorization s anticipated.
The firm’s current ratio calculated as 1.90 for the most recent quarter. The firm past twelve months price to sales ratio was 4.39 and price to cash ratio remained 14.62. As far as the returns are concern, the return on equity was recorded as 11.60% and return on investment was 6.40% while its return on asset stayed at 5.20%. The firm has total debt to equity ratio measured as 0.56.